drug
tucatinib
Marketedupdated 6mo agoby Seagen Inc
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying tucatinib
- phase2Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
- phase3A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
- phase2A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)
- phase3A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
- phase3RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
- phase3T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
- phase2TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- phase2Tucatinib+Trastuzumab+Eribulin in HER2+ MBC
Patent cliff
source: FDA Orange Bookfirst barrier falls
Apr 17, 2027
151 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (14)
- Apr 27, 2038method-of-use (U-3783)US 11207324
- Apr 27, 2038method-of-use (U-3783)US 11207324
- Apr 27, 2038method-of-use (U-3783)US 11666572
- Apr 27, 2038method-of-use (U-3783)US 11666572
- Apr 27, 2038method-of-use (U-3783)US 12048698
- Apr 27, 2038method-of-use (U-3783)US 12048698
- Mar 25, 2033method-of-use (U-2788)US 11504370
- Mar 25, 2033method-of-use (U-2788)US 11504370
- Oct 12, 2032formulationUS 9457093
- Oct 12, 2032formulationUS 9457093
- Jan 14, 2031compositionUS 86480874.2y
- Jan 14, 2031compositionUS 86480874.2y
- May 9, 2027formulationUS 9693989173d
- May 9, 2027formulationUS 9693989173d
FDA exclusivities (6)
- Jan 19, 2030ODE-422Orphan Drug (7y)3.2y
- Jan 19, 2030ODE-422Orphan Drug (7y)3.2y
- Apr 17, 2027ODE-309Orphan Drug (7y)151d
- Apr 17, 2027ODE-309Orphan Drug (7y)151d
- Jan 19, 2026I-906Indication (3y)
- Jan 19, 2026I-906Indication (3y)
News(2)
- FDA review docs spark Revolution sell-off; Zealand diabetes data underwhelm analystsThe new disclosure suggested Rasonque might not be as broadly effective as previously thought. Elsewhere, Ultragenyx got a much-needed cash infusion and TCGX started a China-focused fund.biopharma_dive · 1mo ago
- Post–T-DXd Sacituzumab Govitecan Plus Trastuzumab Yields Low ORR in HER2+ Metastatic Breast CancerSacituzumab govitecan plus trastuzumab following T-DXd did not meet the primary end point of the SATEEN trial in HER2+ metastatic breast cancer.onclive · 6mo ago
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that